Not yet recruiting
Malignant melanoma stage IV+1
Not yet recruitingPhase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma
Registered drugNo placebo
Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma
Registered drugNo placebo
- Disease:Malignant melanoma stage IVMalignant melanoma stage III
- Substances:MomelotinibNivolumab+1
Countries:
Sweden
Sweden- Participants:18–64 years · 65+ years
- Substances:Momelotinib
